Evidence map›Paper›PMID 26711276›Full record

ReviewCurrent neurology and neuroscience reports2016

Advances in Biomarker Research in Parkinson's Disease.

Shyamal H Mehta, Charles H Adler

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current neurology and neuroscience reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Diagnostic biomarkers for Parkinson's disease at a glance: where are we?Journal of neural transmission (Vienna, Austria : 1996) · 2018
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Shyamal H MehtaParkinson's Disease and Movement Disorders Center, Department of Neurology, Mayo Clinic College of Medicine, 13400 E. Shea Boulevard, Scottsdale, AZ, 85259, USA. mehta.shyamal@mayo.edu.
Charles H AdlerParkinson's Disease and Movement Disorders Center, Department of Neurology, Mayo Clinic College of Medicine, 13400 E. Shea Boulevard, Scottsdale, AZ, 85259, USA.
Mayo Clinic in Arizona · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD) is the second most common neurodegenerative disease, and the numbers are projected to double in the next two decades with the increase in the aging population. An important focus of current research is to develop interventions to slow the progression of the disease. However, prerequisites to it include the development of reliable biomarkers for early diagnosis which would identify at-risk groups and disease progression. In this review, we present updated evidence of already known clinical biomarkers (such as hyposmia and rapid eye movement (REM) sleep behavior disorder (RBD)) and neuroimaging biomarkers, as well as newer possible markers in the blood, CSF, and other tissues. While several promising candidates and methods to assess these biomarkers are on the horizon, it is becoming increasingly clear that no one candidate will clearly fulfill all the roles as a single biomarker. A multimodal and combinatorial approach to develop a battery of biomarkers will likely be necessary in the future.

Indexed as

BiomarkersDisease ProgressionEarly DiagnosisHumansMetabolomicsNeuroimagingParkinson DiseaseREM Sleep Behavior DisorderBiomarkersBiomarkersDopaminergic imagingParkinson’s diseaseTranscranial ultrasoundα-synuclein

Identifiers

PMID26711276
OpenAlexW2210398590

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.